A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.

Slides:



Advertisements
Similar presentations
Palumbo A et al. Proc ASH 2013;Abstract 536.
Advertisements

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.
Facon T et al. Proc ASH 2013;Abstract 2.
Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.
Casulo C et al. Proc ASH 2013;Abstract 510.
Richardson PG et al. Proc ASH 2013;Abstract 535.
Palumbo A et al. Proc ASH 2012;Abstract 446.
LaCasce A et al. Proc ASH 2014;Abstract 293.
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma 1,2 The Cardiovascular Impact of Carfilzomib in Multiple Myeloma 3 1 Stewart.
1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.
Korde N et al. Proc ASH 2014;Abstract 2105.
Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach for Proteasome-Inhibitor Based Therapy in Waldenstrom’s.
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
Corre J et al. Proc ASH 2014;Abstract 180.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Arsenic Trioxide (ATO) in the Consolidation Treatment of Newly Diagnosed APL — First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian.
Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates.
Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.
Palumbo A et al. Proc ASH 2014;Abstract 175.
Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.
Lenalidomide, Bortezomib and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MM): Updated Results of a Multicenter Phase I/II Study After.
Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.
Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients Palumbo A.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.
Ruan J et al. Proc ASH 2013;Abstract 247.
Rituximab Maintenance versus Wait and Watch After Four Courses of R-DHAP Followed by Autologous Stem Cell Transplantation in Previously Untreated Young.
A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.
Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide plus Low Dose Dex (Rd) (Phase III Spanish Trial): Persistent Benefit.
Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.
ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Mark TM et al. Proc ASH 2012;Abstract 77.
A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.
Continued Overall Survival Benefit After 5 Years’ Follow-Up with Bortezomib-Melphalan-Prednisone (VMP) versus Melphalan-Prednisone (MP) in Patients with.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 Friedberg.
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,
Pomalidomide + Low-Dose Dexamethasone (POM + LoDex) vs High-Dose Dexamethasone (HiDex) in Relapsed/Refractory Multiple Myeloma (RRMM): MM-003 Analysis.
Morie Gertz Chair Dept. of Medicine
Palumbo A et al. Proc ASH 2012;Abstract 200.
Attal M et al. Proc ASH 2010;Abstract 310.
Korde N et al. Proc ASH 2012;Abstract 732.
IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*
Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.
Mateos MV et al. Proc ASH 2013;Abstract 403.
San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.
Goede V et al. Proc ASH 2014;Abstract 3327.
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
Treatment of Immunoglobulin Light Chain Amyloidosis
Challenging Cases in Multiple Myeloma Panel Discussion
Fowler NH et al. Proc ASCO 2010;Abstract 8036.
Rossi A et al. Proc ASCO 2011;Abstract 8008.
Niesvizky R et al. Proc ASH 2010;Abstract 619.
Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.
Coiffier B et al. Proc ASH 2010;Abstract 857.
Vitolo U et al. Proc ASH 2011;Abstract 777.
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p  Sandy W. Wong, Ute Hegenbart, Giovanni Palladini,
Forero-Torres A et al. Proc ASH 2011;Abstract 3711.
Zaja F et al. Proc ASH 2010;Abstract 966.
Ahmadi T et al. Proc ASH 2011;Abstract 266.
Boccadoro M et al. Proc ASCO 2011;Abstract 8020.
Presentation transcript:

A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis Palladini G et al. Proc ASH 2014;Abstract 305.

Background Early small studies have reported unprecedented response rates for patients with systemic light chain (AL) amyloidosis treated with the combination of cyclophosphamide, bortezomib and dexamethasone (CyBorD) (Blood 2012;119(19):4391). –Response rate: 94% –Complete hematologic response: 71% Based on these results, CyBorD has become one of the most commonly prescribed front-line regimens in AL amyloidosis outside of clinical trials. Subsequently, it was shown that CyBorD is unable to overcome the poor prognosis of patients with advanced cardiac disease (Blood 2013;121(17):3420-7). Study objective: To assess the role of CyBorD as up-front treatment for patients with AL amyloidosis. Palladini G et al. Proc ASH 2014;Abstract 305 (Abstract only).

Study Methods Prospectively maintained databases of the London National Amyloidosis Centre and the Pavia Amyloidosis Research and Treatment Center were searched for newly diagnosed patients who received CyBorD between 2006 and Number of patients identified (n = 230) –Median estimated glomerular filtration rate: 82 mL/min –Median bone marrow plasma cell infiltrate: 12% –Difference between involved and noninvolved free light chain (dFLC): 248 mg/L Cyclophosphamide: 300 mg/m 2 on d1, 8, 15 Bortezomib: 1.0 mg/m 2 q1wk to 1.3 mg/m 2 twice weekly Dexamethasone: Mostly 10, 20 or 40 mg per week –69 patients (30%) received ≥160 mg/week Median number of cycles: 4 (range, 1-8) Palladini G et al. Proc ASH 2014;Abstract 305 (Abstract only).

Patient Characteristics Characteristic N = 230 Median age (range)60 years (38-85) Involved organs: Heart169 (73%) Kidney149 (65%) Soft tissues35 (15%) Liver25 (11%) Peripheral nervous system6 (3%) Cardiac disease: Stage I41 (18%) Stage II77 (33%) Stage III112 (49%) N-terminal pronatriuretic peptide type B >8,500 ng/L51 (22%) Palladini G et al. Proc ASH 2014;Abstract 305 (Abstract only). 201 patients with measurable disease

Response in Intent-to-Treat (ITT) Population Response rate (All ITT) n = 201* Hematologic response62% Complete response (CR)42 (21%) Very good partial response (VGPR)45 (22%) Cardiac Stage I Hematologic response77% ≥VGPR56% Cardiac Stage IIIB Hematologic response42% ≥VGPR23% * Evaluable patients (40 deaths before response evaluation) Response was affected by cardiac stage. Palladini G et al. Proc ASH 2014;Abstract 305.

Response by NT-proBNP and Second-Line Therapy Patients with N-terminal pronatriuretic peptide type B (NT-proBNP) >8,500 ng/L who achieved a response: 37% –Patients alive at 12 months: 28% –Responders in this group: 85% –Achieved CR/VGPR: 69% The most common second-line treatments: –Autologous stem cell transplant (ASCT) (n = 17) –Response rate: 65% –CR: 47% –Lenalidomide/dexamethasone (n = 20) –Response rate: 65% –CR: 10% Palladini G et al. Proc ASH 2014;Abstract 305 (Abstract only).

Cardiac and Renal Response Patients with renal responses: 27% Cardiac response decreased with increasing cardiac stage: –In patients with Stage II disease: 29% –In patients with Stage IIIA disease: 17% –In patients with Stage IIIB disease: 4% Palladini G et al. Proc ASH 2014;Abstract 305.

Survival Outcomes Median survival for all patients: 72 months After a median follow-up of 25 months: –Deaths: 94 (41%) –Estimated 5-year survival: –For patients with Stage I disease: 100% –For patients with Stage II disease: 52% –For patients with Stage III disease: 27% Palladini G et al. Proc ASH 2014;Abstract 305 (Abstract only).

Treatment Outcomes Cardiac staging was the main factor affecting survival. There were no deaths among patients with Stage I disease without cardiac involvement. Survival was similar between patients with Stage II and Stage IIIA disease –Indicating that this regimen can rescue and improve survival of some patients with advanced disease However, the survival of patients with advanced cardiac Stage IIIB disease was still poor –Median survival: 7 months Palladini G et al. Proc ASH 2014;Abstract 305.

Treatment Outcomes (continued) Response improved survival only in patients with Stage II or Stage IIIA disease, with best survival outcomes in those who achieved VGPR or CR. There was an improvement of survival in patients who achieved PR. Patients with Stage IIIB disease who survived until the landmark analysis at 3 months survived longer if they responded to treatment. Palladini G et al. Proc ASH 2014;Abstract 305.

Author Conclusions This is the largest study of CyBorD treatment in AL amyloidosis. This study confirms that CyBorD is remarkably effective in patients at low risk, with 56% CR/VGPR and no deaths observed in patients with Stage I disease. Unfortunately, outcomes in patients with advanced cardiac disease were poor. –However, 28% of these patients who achieved a CR or VGPR had improved survival, showing the importance of striving for a good response even in this poor-risk group. The very high clonal response and excellent outcome in early- stage AL with CyBorD therapy confirm its place as a regimen of choice for this group and raise the need for a randomized trial assessing the role of up-front ASCT in this era of novel agent- based therapy in AL amyloidosis. Palladini G et al. Proc ASH 2014;Abstract 305 (Abstract only).

Investigator Commentary: A European Collaborative Study to Determine the Role of Up-Front CyBorD in AL Amyloidosis This is an important study of 230 patients with AL amyloidosis who received up-front CyBorD therapy. Most oncologists treat AL amyloidosis with CyBorD based on information from a series of smaller studies. Hence, this large study was initiated and showed that 56% of patients with cardiac Stage I disease achieved VGPR or better. For patients with advanced cardiac disease, the outcome was worse, but 28% of these patients achieved CR or VGPR. For these patients, survival was improved. One could evaluate these results from different perspectives and say that it’s better to administer CyBorD to patients with low-risk disease than to those at high risk. On the other hand, for high-risk disease, whatever therapy is used will result in a worse outcome. Also, one could probably interpret the results to say that this therapy works for both high-risk and low-risk disease, but, as expected, it’s even better for patients with low-risk disease. Such deep responses with this regimen, similar to those seen in newly diagnosed and relapsed multiple myeloma, raise the question of what the role is for up-front ASCT in AL amyloidosis. The high clonal response and excellent outcome with CyBorD in early-stage AL amyloidosis necessitate a randomized study of up-front versus delayed ASCT in this setting. Interview with Ola Landgren, MD, PhD, February 9, 2015